APO Research
Talk to an analyst

APO RESEARCH · REPORT

Liposomal Amphoteracin B

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Liposomal Amphoteracin B Market Outlook and Growth Opportunities 2026

2 January 2026194 pages

Choose your research edition.

Industry ResearchLiposomal Amphoteracin B Industry Research Report 2026106 pages · $2,950 USDIndustry Growth & TrendsGlobal Liposomal Amphoteracin B Industry Growth and Trends Forecast to 203275 pages · $3,450 USDMarket StructureGlobal Liposomal Amphoteracin B Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032178 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Liposomal Amphoteracin B Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Liposomal Amphoteracin B Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Liposomal Amphoteracin B market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Liposomal Amphoteracin B is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Liposomal Amphoteracin B is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Liposomal Amphoteracin B is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Liposomal Amphoteracin B market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Liposomal Amphoteracin B market include Gilead Sciences and Cipla among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Liposomal Amphoteracin B market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Liposomal Amphoteracin B and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Liposomal Amphoteracin B sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Liposomal Amphoteracin B market size, projected growth trends, production technologies, key applications, and end-use industries.

Liposomal Amphoteracin B Segment by Company

Gilead Sciences

Cipla

Liposomal Amphoteracin B Segment by Type

25mg

50mg

Liposomal Amphoteracin B Segment by Application

Hospital

Pharmacy

Liposomal Amphoteracin B Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Liposomal Amphoteracin B status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Liposomal Amphoteracin B market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Liposomal Amphoteracin B significant trends, drivers, influence factors in global and regions.

6. To analyze Liposomal Amphoteracin B competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Liposomal Amphoteracin B market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Liposomal Amphoteracin B and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Liposomal Amphoteracin B.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Liposomal Amphoteracin B market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Liposomal Amphoteracin B industry.

Chapter 3: Detailed analysis of Liposomal Amphoteracin B manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Liposomal Amphoteracin B in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Liposomal Amphoteracin B in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Liposomal Amphoteracin B Industry Trends Table 2. Liposomal Amphoteracin B Industry Drivers Table 3. Liposomal Amphoteracin B Industry Opportunities and Challenges Table 4. Liposomal Amphoteracin B Industry Restraints Table 5. Global Liposomal Amphoteracin B Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Liposomal Amphoteracin B Revenue Share by Company (2021-2026) Table 7. Global Liposomal Amphoteracin B Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Liposomal Amphoteracin B Sales Volume Share by Company (2021-2026) Table 9. Global Liposomal Amphoteracin B Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Liposomal Amphoteracin B Company Ranking, (2024-2026) & (USD Million) Table 11. Global Liposomal Amphoteracin B Key Company Manufacturing Base & Headquarters Table 12. Global Liposomal Amphoteracin B Company, Product Type & Application Table 13. Global Liposomal Amphoteracin B Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Liposomal Amphoteracin B by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of 25mg Table 18. Significant Companies of 50mg Table 19. Global Liposomal Amphoteracin B Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Liposomal Amphoteracin B Sales Volume by Type (2021-2026) & (K Units) Table 21. Global Liposomal Amphoteracin B Sales Volume by Type (2027-2032) & (K Units) Table 22. Global Liposomal Amphoteracin B Sales Volume Share by Type (2021-2026) Table 23. Global Liposomal Amphoteracin B Sales Volume Share by Type (2027-2032) Table 24. Global Liposomal Amphoteracin B Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Liposomal Amphoteracin B Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Liposomal Amphoteracin B Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Liposomal Amphoteracin B Sales Value Share by Type (2021-2026) Table 28. Global Liposomal Amphoteracin B Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Hospital Table 30. Significant Companies of Pharmacy Table 31. Global Liposomal Amphoteracin B Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 32. Global Liposomal Amphoteracin B Sales Volume by Application (2021-2026) & (K Units) Table 33. Global Liposomal Amphoteracin B Sales Volume by Application (2027-2032) & (K Units) Table 34. Global Liposomal Amphoteracin B Sales Volume Share by Application (2021-2026) Table 35. Global Liposomal Amphoteracin B Sales Volume Share by Application (2027-2032) Table 36. Global Liposomal Amphoteracin B Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Liposomal Amphoteracin B Sales Value by Application (2021-2026) & (US$ Million) Table 38. Global Liposomal Amphoteracin B Sales Value by Application (2027-2032) & (US$ Million) Table 39. Global Liposomal Amphoteracin B Sales Value Share by Application (2021-2026) Table 40. Global Liposomal Amphoteracin B Sales Value Share by Application (2027-2032) Table 41. Global Liposomal Amphoteracin B Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 42. Global Liposomal Amphoteracin B Sales by Region (2021-2026) & (K Units) Table 43. Global Liposomal Amphoteracin B Sales Market Share by Region (2021-2026) Table 44. Global Liposomal Amphoteracin B Sales by Region (2027-2032) & (K Units) Table 45. Global Liposomal Amphoteracin B Sales Market Share by Region (2027-2032) Table 46. Global Liposomal Amphoteracin B Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Liposomal Amphoteracin B Sales Value by Region (2021-2026) & (US$ Million) Table 48. Global Liposomal Amphoteracin B Sales Value Share by Region (2021-2026) Table 49. Global Liposomal Amphoteracin B Sales Value by Region (2027-2032) & (US$ Million) Table 50. Global Liposomal Amphoteracin B Sales Value Share by Region (2027-2032) Table 51. Global Liposomal Amphoteracin B Market Average Price (US$/Unit) by Region (2021-2026) Table 52. Global Liposomal Amphoteracin B Market Average Price (US$/Unit) by Region (2027-2032) Table 53. Global Liposomal Amphoteracin B Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. Global Liposomal Amphoteracin B Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 55. Global Liposomal Amphoteracin B Sales by Country (2021-2026) & (K Units) Table 56. Global Liposomal Amphoteracin B Sales Market Share by Country (2021-2026) Table 57. Global Liposomal Amphoteracin B Sales by Country (2027-2032) & (K Units) Table 58. Global Liposomal Amphoteracin B Sales Market Share by Country (2027-2032) Table 59. Global Liposomal Amphoteracin B Sales Value by Country (2021-2026) & (US$ Million) Table 60. Global Liposomal Amphoteracin B Sales Value Market Share by Country (2021-2026) Table 61. Global Liposomal Amphoteracin B Sales Value by Country (2027-2032) & (US$ Million) Table 62. Global Liposomal Amphoteracin B Sales Value Market Share by Country (2027-2032) Table 63. Gilead Sciences Company Information Table 64. Gilead Sciences Business Overview Table 65. Gilead Sciences Liposomal Amphoteracin B Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Gilead Sciences Liposomal Amphoteracin B Product Portfolio Table 67. Gilead Sciences Recent Development Table 68. Cipla Company Information Table 69. Cipla Business Overview Table 70. Cipla Liposomal Amphoteracin B Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Cipla Liposomal Amphoteracin B Product Portfolio Table 72. Cipla Recent Development Table 73. Key Raw Materials Table 74. Raw Materials Key Suppliers Table 75. Liposomal Amphoteracin B Distributors List Table 76. Liposomal Amphoteracin B Customers List Table 77. Research Programs/Design for This Report Table 78. Authors List of This Report Table 79. Secondary Sources Table 80. Primary Sources List of Figures Figure 1. Liposomal Amphoteracin B Product Image Figure 2. Global Liposomal Amphoteracin B Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Liposomal Amphoteracin B Sales Value (2021-2032) & (US$ Million) Figure 4. Global Liposomal Amphoteracin B Sales (2021-2032) & (K Units) Figure 5. Global Liposomal Amphoteracin B Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Liposomal Amphoteracin B Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. 25mg Image Figure 10. 50mg Image Figure 11. Global Liposomal Amphoteracin B Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Liposomal Amphoteracin B Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Liposomal Amphoteracin B Sales Volume Share by Type (2021-2032) Figure 14. Global Liposomal Amphoteracin B Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Liposomal Amphoteracin B Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Liposomal Amphoteracin B Sales Value Share by Type (2021-2032) Figure 17. Hospital Image Figure 18. Pharmacy Image Figure 19. Global Liposomal Amphoteracin B Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 20. Global Liposomal Amphoteracin B Sales Volume Share 2021 VS 2025 VS 2032 Figure 21. Global Liposomal Amphoteracin B Sales Volume Share by Application (2021-2032) Figure 22. Global Liposomal Amphoteracin B Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Liposomal Amphoteracin B Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global Liposomal Amphoteracin B Sales Value Share by Application (2021-2032) Figure 25. Global Liposomal Amphoteracin B Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 26. Global Liposomal Amphoteracin B Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 27. Global Liposomal Amphoteracin B Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 28. Global Liposomal Amphoteracin B Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 29. North America Liposomal Amphoteracin B Sales Value (2021-2032) & (US$ Million) Figure 30. North America Liposomal Amphoteracin B Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Europe Liposomal Amphoteracin B Sales Value (2021-2032) & (US$ Million) Figure 32. Europe Liposomal Amphoteracin B Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Asia-Pacific Liposomal Amphoteracin B Sales Value (2021-2032) & (US$ Million) Figure 34. Asia-Pacific Liposomal Amphoteracin B Sales Value Share by Country (%), 2025 VS 2032 Figure 35. South America Liposomal Amphoteracin B Sales Value (2021-2032) & (US$ Million) Figure 36. South America Liposomal Amphoteracin B Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Middle East & Africa Liposomal Amphoteracin B Sales Value (2021-2032) & (US$ Million) Figure 38. Middle East & Africa Liposomal Amphoteracin B Sales Value Share by Country (%), 2025 VS 2032 Figure 39. USA Liposomal Amphoteracin B Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. USA Liposomal Amphoteracin B Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. USA Liposomal Amphoteracin B Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Canada Liposomal Amphoteracin B Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Canada Liposomal Amphoteracin B Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Canada Liposomal Amphoteracin B Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Mexico Liposomal Amphoteracin B Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Mexico Liposomal Amphoteracin B Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Mexico Liposomal Amphoteracin B Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Germany Liposomal Amphoteracin B Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Germany Liposomal Amphoteracin B Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Germany Liposomal Amphoteracin B Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. France Liposomal Amphoteracin B Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. France Liposomal Amphoteracin B Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. France Liposomal Amphoteracin B Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. U.K. Liposomal Amphoteracin B Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. U.K. Liposomal Amphoteracin B Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. U.K. Liposomal Amphoteracin B Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Italy Liposomal Amphoteracin B Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Italy Liposomal Amphoteracin B Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Italy Liposomal Amphoteracin B Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Spain Liposomal Amphoteracin B Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Spain Liposomal Amphoteracin B Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Spain Liposomal Amphoteracin B Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Russia Liposomal Amphoteracin B Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Russia Liposomal Amphoteracin B Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Russia Liposomal Amphoteracin B Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Netherlands Liposomal Amphoteracin B Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Netherlands Liposomal Amphoteracin B Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Netherlands Liposomal Amphoteracin B Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Nordic Countries Liposomal Amphoteracin B Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Nordic Countries Liposomal Amphoteracin B Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Nordic Countries Liposomal Amphoteracin B Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. China Liposomal Amphoteracin B Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. China Liposomal Amphoteracin B Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. China Liposomal Amphoteracin B Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Japan Liposomal Amphoteracin B Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Japan Liposomal Amphoteracin B Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Japan Liposomal Amphoteracin B Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. South Korea Liposomal Amphoteracin B Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. South Korea Liposomal Amphoteracin B Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. South Korea Liposomal Amphoteracin B Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. India Liposomal Amphoteracin B Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. India Liposomal Amphoteracin B Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. India Liposomal Amphoteracin B Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Australia Liposomal Amphoteracin B Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Australia Liposomal Amphoteracin B Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Australia Liposomal Amphoteracin B Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Southeast Asia Liposomal Amphoteracin B Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Southeast Asia Liposomal Amphoteracin B Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Southeast Asia Liposomal Amphoteracin B Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Brazil Liposomal Amphoteracin B Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Brazil Liposomal Amphoteracin B Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Brazil Liposomal Amphoteracin B Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Argentina Liposomal Amphoteracin B Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Argentina Liposomal Amphoteracin B Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Argentina Liposomal Amphoteracin B Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Chile Liposomal Amphoteracin B Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Chile Liposomal Amphoteracin B Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Chile Liposomal Amphoteracin B Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Colombia Liposomal Amphoteracin B Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Colombia Liposomal Amphoteracin B Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Colombia Liposomal Amphoteracin B Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Peru Liposomal Amphoteracin B Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Peru Liposomal Amphoteracin B Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Peru Liposomal Amphoteracin B Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Saudi Arabia Liposomal Amphoteracin B Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Saudi Arabia Liposomal Amphoteracin B Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Liposomal Amphoteracin B Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Israel Liposomal Amphoteracin B Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Israel Arabia Liposomal Amphoteracin B Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Israel Arabia Liposomal Amphoteracin B Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. UAE Liposomal Amphoteracin B Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. UAE Liposomal Amphoteracin B Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. UAE Liposomal Amphoteracin B Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Turkey Liposomal Amphoteracin B Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Turkey Liposomal Amphoteracin B Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Turkey Liposomal Amphoteracin B Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Iran Liposomal Amphoteracin B Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Iran Liposomal Amphoteracin B Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Iran Liposomal Amphoteracin B Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Egypt Liposomal Amphoteracin B Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Egypt Liposomal Amphoteracin B Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Egypt Liposomal Amphoteracin B Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Liposomal Amphoteracin B Value Chain Figure 124. Manufacturing Cost Structure Figure 125. Liposomal Amphoteracin B Sales Mode & Process Figure 126. Direct Comparison with Distribution Share Figure 127. Distributors Profiles Figure 128. Years Considered Figure 129. Research Process Figure 130. Key Executives Interviewed

Scope & coverage.

Types
  • 25mg
  • 50mg
Applications
  • Hospital
  • Pharmacy
Companies covered
  • Gilead Sciences
  • Cipla

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Liposomal Amphoteracin B Sales Value (2021-2032)
  4. 1.2.2 Global Liposomal Amphoteracin B Sales Volume (2021-2032)
  5. 1.2.3 Global Liposomal Amphoteracin B Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Liposomal Amphoteracin B Market Dynamics
  1. 2.1 Liposomal Amphoteracin B Industry Trends
  2. 2.2 Liposomal Amphoteracin B Industry Drivers
  3. 2.3 Liposomal Amphoteracin B Industry Opportunities and Challenges
  4. 2.4 Liposomal Amphoteracin B Industry Restraints
3 Liposomal Amphoteracin B Market by Company
  1. 3.1 Global Liposomal Amphoteracin B Company Revenue Ranking in 2025
  2. 3.2 Global Liposomal Amphoteracin B Revenue by Company (2021-2026)
  3. 3.3 Global Liposomal Amphoteracin B Sales Volume by Company (2021-2026)
  4. 3.4 Global Liposomal Amphoteracin B Average Price by Company (2021-2026)
  5. 3.5 Global Liposomal Amphoteracin B Company Ranking (2024-2026)
  6. 3.6 Global Liposomal Amphoteracin B Company Manufacturing Base and Headquarters
  7. 3.7 Global Liposomal Amphoteracin B Company Product Type and Application
  8. 3.8 Global Liposomal Amphoteracin B Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Liposomal Amphoteracin B Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Liposomal Amphoteracin B Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Liposomal Amphoteracin B Market by Type
  1. 4.1 Liposomal Amphoteracin B Type Introduction
  2. 4.1.1 25mg
  3. 4.1.2 50mg
  4. 4.2 Global Liposomal Amphoteracin B Sales Volume by Type
  5. 4.2.1 Global Liposomal Amphoteracin B Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Liposomal Amphoteracin B Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Liposomal Amphoteracin B Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Liposomal Amphoteracin B Sales Value by Type
  9. 4.3.1 Global Liposomal Amphoteracin B Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Liposomal Amphoteracin B Sales Value by Type (2021-2032)
  11. 4.3.3 Global Liposomal Amphoteracin B Sales Value Share by Type (2021-2032)
5 Liposomal Amphoteracin B Market by Application
  1. 5.1 Liposomal Amphoteracin B Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Pharmacy
  4. 5.2 Global Liposomal Amphoteracin B Sales Volume by Application
  5. 5.2.1 Global Liposomal Amphoteracin B Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Liposomal Amphoteracin B Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Liposomal Amphoteracin B Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Liposomal Amphoteracin B Sales Value by Application
  9. 5.3.1 Global Liposomal Amphoteracin B Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Liposomal Amphoteracin B Sales Value by Application (2021-2032)
  11. 5.3.3 Global Liposomal Amphoteracin B Sales Value Share by Application (2021-2032)
6 Liposomal Amphoteracin B Regional Sales and Value Analysis
  1. 6.1 Global Liposomal Amphoteracin B Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Liposomal Amphoteracin B Sales by Region (2021-2032)
  3. 6.2.1 Global Liposomal Amphoteracin B Sales by Region: 2021-2026
  4. 6.2.2 Global Liposomal Amphoteracin B Sales by Region (2027-2032)
  5. 6.3 Global Liposomal Amphoteracin B Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Liposomal Amphoteracin B Sales Value by Region (2021-2032)
  7. 6.4.1 Global Liposomal Amphoteracin B Sales Value by Region: 2021-2026
  8. 6.4.2 Global Liposomal Amphoteracin B Sales Value by Region (2027-2032)
  9. 6.5 Global Liposomal Amphoteracin B Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Liposomal Amphoteracin B Sales Value (2021-2032)
  12. 6.6.2 North America Liposomal Amphoteracin B Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Liposomal Amphoteracin B Sales Value (2021-2032)
  15. 6.7.2 Europe Liposomal Amphoteracin B Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Liposomal Amphoteracin B Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Liposomal Amphoteracin B Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Liposomal Amphoteracin B Sales Value (2021-2032)
  21. 6.9.2 South America Liposomal Amphoteracin B Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Liposomal Amphoteracin B Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Liposomal Amphoteracin B Sales Value Share by Country, 2025 VS 2032
7 Liposomal Amphoteracin B Country-level Sales and Value Analysis
  1. 7.1 Global Liposomal Amphoteracin B Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Liposomal Amphoteracin B Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Liposomal Amphoteracin B Sales by Country (2021-2032)
  4. 7.3.1 Global Liposomal Amphoteracin B Sales by Country (2021-2026)
  5. 7.3.2 Global Liposomal Amphoteracin B Sales by Country (2027-2032)
  6. 7.4 Global Liposomal Amphoteracin B Sales Value by Country (2021-2032)
  7. 7.4.1 Global Liposomal Amphoteracin B Sales Value by Country (2021-2026)
  8. 7.4.2 Global Liposomal Amphoteracin B Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Liposomal Amphoteracin B Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Liposomal Amphoteracin B Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Liposomal Amphoteracin B Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Liposomal Amphoteracin B Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Liposomal Amphoteracin B Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Liposomal Amphoteracin B Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Liposomal Amphoteracin B Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Liposomal Amphoteracin B Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Liposomal Amphoteracin B Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Liposomal Amphoteracin B Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Liposomal Amphoteracin B Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Liposomal Amphoteracin B Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Liposomal Amphoteracin B Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Liposomal Amphoteracin B Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Liposomal Amphoteracin B Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Liposomal Amphoteracin B Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Liposomal Amphoteracin B Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Liposomal Amphoteracin B Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Liposomal Amphoteracin B Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Liposomal Amphoteracin B Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Liposomal Amphoteracin B Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Liposomal Amphoteracin B Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Liposomal Amphoteracin B Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Liposomal Amphoteracin B Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Liposomal Amphoteracin B Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Liposomal Amphoteracin B Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Liposomal Amphoteracin B Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Liposomal Amphoteracin B Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Liposomal Amphoteracin B Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Liposomal Amphoteracin B Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Liposomal Amphoteracin B Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Liposomal Amphoteracin B Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Liposomal Amphoteracin B Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Liposomal Amphoteracin B Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Liposomal Amphoteracin B Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Liposomal Amphoteracin B Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Liposomal Amphoteracin B Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Liposomal Amphoteracin B Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Liposomal Amphoteracin B Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Liposomal Amphoteracin B Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Liposomal Amphoteracin B Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Liposomal Amphoteracin B Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Liposomal Amphoteracin B Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Liposomal Amphoteracin B Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Liposomal Amphoteracin B Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Liposomal Amphoteracin B Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Liposomal Amphoteracin B Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Liposomal Amphoteracin B Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Liposomal Amphoteracin B Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Liposomal Amphoteracin B Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Liposomal Amphoteracin B Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Liposomal Amphoteracin B Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Liposomal Amphoteracin B Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Liposomal Amphoteracin B Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Liposomal Amphoteracin B Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Liposomal Amphoteracin B Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Liposomal Amphoteracin B Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Liposomal Amphoteracin B Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Liposomal Amphoteracin B Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Liposomal Amphoteracin B Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Liposomal Amphoteracin B Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Liposomal Amphoteracin B Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Liposomal Amphoteracin B Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Liposomal Amphoteracin B Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Liposomal Amphoteracin B Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Liposomal Amphoteracin B Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Liposomal Amphoteracin B Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Liposomal Amphoteracin B Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Liposomal Amphoteracin B Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Liposomal Amphoteracin B Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Liposomal Amphoteracin B Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Liposomal Amphoteracin B Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Liposomal Amphoteracin B Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Liposomal Amphoteracin B Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Liposomal Amphoteracin B Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Liposomal Amphoteracin B Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Liposomal Amphoteracin B Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Liposomal Amphoteracin B Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Liposomal Amphoteracin B Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Liposomal Amphoteracin B Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Liposomal Amphoteracin B Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Liposomal Amphoteracin B Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Liposomal Amphoteracin B Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Liposomal Amphoteracin B Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Gilead Sciences
  2. 8.1.1 Gilead Sciences Company Information
  3. 8.1.2 Gilead Sciences Business Overview
  4. 8.1.3 Gilead Sciences Liposomal Amphoteracin B Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Gilead Sciences Liposomal Amphoteracin B Product Portfolio
  6. 8.1.5 Gilead Sciences Recent Developments
  7. 8.2 Cipla
  8. 8.2.1 Cipla Company Information
  9. 8.2.2 Cipla Business Overview
  10. 8.2.3 Cipla Liposomal Amphoteracin B Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Cipla Liposomal Amphoteracin B Product Portfolio
  12. 8.2.5 Cipla Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Liposomal Amphoteracin B Value Chain Analysis
  2. 9.1.1 Liposomal Amphoteracin B Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Liposomal Amphoteracin B Sales Mode & Process
  6. 9.2 Liposomal Amphoteracin B Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Liposomal Amphoteracin B Distributors
  9. 9.2.3 Liposomal Amphoteracin B Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst